Brandon Walsh

2.9k total citations · 2 hit papers
15 papers, 2.3k citations indexed

About

Brandon Walsh is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Brandon Walsh has authored 15 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in Brandon Walsh's work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Management and Research (5 papers). Brandon Walsh is often cited by papers focused on Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Management and Research (5 papers). Brandon Walsh collaborates with scholars based in United States, Netherlands and Canada. Brandon Walsh's co-authors include Stuart N. Seidman, Robyn Sysko, Madelyn S. Gould, Lisa E. Porter, Ken Wilhelm, Ping Yan, Jaret Malloy, Richard M. Bergenstal, Carol Wysham and Leigh MacConell and has published in prestigious journals such as The Lancet, JAMA and Gastroenterology.

In The Last Decade

Brandon Walsh

15 papers receiving 2.2k citations

Hit Papers

Placebo Response in Studies of Major Depression 2002 2026 2010 2018 2002 2010 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Placebo Response in Studies of Major Depression
    2002 833 citations Brandon Walsh, Stuart N. Seidman et al. JAMA profile →
  2. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    2010 510 citations Richard M. Bergenstal, Carol Wysham et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brandon Walsh United States 14 1.1k 748 489 467 369 15 2.3k
Stephen Wright United Kingdom 30 290 0.3× 2.7k 3.5× 332 0.7× 563 1.2× 519 1.4× 67 4.5k
Hossam A. Shaltout United States 27 402 0.4× 279 0.4× 262 0.5× 246 0.5× 156 0.4× 102 2.0k
Michael Schwiers United States 17 1.2k 1.1× 1.5k 2.0× 181 0.4× 366 0.8× 124 0.3× 36 2.8k
Mong‐Liang Lu Taiwan 30 374 0.3× 295 0.4× 549 1.1× 113 0.2× 204 0.6× 128 2.9k
Anna Ferrulli Italy 28 322 0.3× 163 0.2× 287 0.6× 218 0.5× 194 0.5× 79 2.9k
Fabio Caputo Italy 32 313 0.3× 239 0.3× 352 0.7× 172 0.4× 120 0.3× 112 3.2k
Peter Manu United States 29 556 0.5× 314 0.4× 163 0.3× 199 0.4× 112 0.3× 108 3.2k
Martin Birkett United States 20 615 0.5× 367 0.5× 147 0.3× 108 0.2× 103 0.3× 26 2.3k
Isela Esther Juárez‐Rojop Mexico 23 359 0.3× 175 0.2× 288 0.6× 128 0.3× 116 0.3× 158 2.1k
Donna A. Wirshing United States 28 549 0.5× 379 0.5× 266 0.5× 103 0.2× 266 0.7× 50 3.4k

Countries citing papers authored by Brandon Walsh

Since Specialization
Citations

This map shows the geographic impact of Brandon Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon Walsh more than expected).

Fields of papers citing papers by Brandon Walsh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon Walsh. The network helps show where Brandon Walsh may publish in the future.

Co-authorship network of co-authors of Brandon Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon Walsh. A scholar is included among the top collaborators of Brandon Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon Walsh. Brandon Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Walsh, Brandon, et al.. (2019). MUCORMYCOSIS AND CANDIDEMIA FOLLOWING ECULIZUMAB TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME. CHEST Journal. 156(4). A1212–A1212. 1 indexed citations
3.
4.
5.
Fujioka, Ken, Raymond A Plodkowski, Patrick M. O’Neil, et al.. (2016). The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. International Journal of Obesity. 40(9). 1369–1375. 57 indexed citations
6.
Halseth, Amy E., Kevin Shan, Brandon Walsh, Kye Gilder, & Ken Fujioka. (2016). Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity. 25(2). 338–345. 29 indexed citations
7.
Stonehouse, Anthony H., Brandon Walsh, & Robert Cuddihy. (2011). Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies. Diabetes Technology & Therapeutics. 13(10). 1063–1069. 23 indexed citations
8.
Wysham, Carol, Richard M. Bergenstal, Jaret Malloy, et al.. (2011). DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide. Diabetic Medicine. 28(6). 705–714. 101 indexed citations
9.
Taylor, Kristin, et al.. (2011). Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocrine Disorders. 11(1). 9–9. 56 indexed citations
10.
Fineman, Mark, Shawn Flanagan, Kristin Taylor, et al.. (2010). Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing. Clinical Pharmacokinetics. 50(1). 65–74. 117 indexed citations
11.
Bergenstal, Richard M., Carol Wysham, Leigh MacConell, et al.. (2010). Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet. 376(9739). 431–439. 510 indexed citations breakdown →
12.
Buse, John B., Daniel J. Drucker, Kristin Taylor, et al.. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 33(6). 1255–1261. 282 indexed citations
13.
Trevaskis, James L., Todd Coffey, Rebecca L. Cole, et al.. (2008). Amylin-Mediated Restoration of Leptin Responsiveness in Diet-Induced Obesity: Magnitude and Mechanisms. Endocrinology. 149(11). 5679–5687. 125 indexed citations
14.
Walsh, Brandon, Stuart N. Seidman, Robyn Sysko, & Madelyn S. Gould. (2002). Placebo Response in Studies of Major Depression. JAMA. 287(14). 1840–1840. 833 indexed citations breakdown →
15.
Walsh, Brandon. (1975). Recognition of Streptococcal Pharyngitis in Adults. Archives of Internal Medicine. 135(11). 1493–1493. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Wright Breakdown of academic impact, for papers by Hossam A. Shaltout Breakdown of academic impact, for papers by Michael Schwiers Breakdown of academic impact, for papers by Mong‐Liang Lu Breakdown of academic impact, for papers by Anna Ferrulli Breakdown of academic impact, for papers by Fabio Caputo Breakdown of academic impact, for papers by Peter Manu Breakdown of academic impact, for papers by Martin Birkett Breakdown of academic impact, for papers by Isela Esther Juárez‐Rojop Breakdown of academic impact, for papers by Donna A. Wirshing
Rankless by CCL
2026